Patents by Inventor Hiromi Nara
Hiromi Nara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9902782Abstract: Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.Type: GrantFiled: May 3, 2017Date of Patent: February 27, 2018Assignee: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Shigenori Yagi, Yoshinori Ishii, Hiromi Nara
-
Publication number: 20170253669Abstract: Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.Type: ApplicationFiled: May 3, 2017Publication date: September 7, 2017Applicant: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Shigenori YAGI, Yoshinori ISHll, Hiromi NARA
-
Patent number: 9683051Abstract: Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.Type: GrantFiled: April 21, 2016Date of Patent: June 20, 2017Assignee: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Shigenori Yagi, Yoshinori Ishii, Hiromi Nara
-
Publication number: 20160222130Abstract: Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.Type: ApplicationFiled: April 21, 2016Publication date: August 4, 2016Applicant: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Shigenori Yagi, Yoshinori Ishii, Hiromi Nara
-
Publication number: 20130308294Abstract: According to one embodiment, a luminaire includes a substrate, a light-emitting section mounted on the substrate and including a light-emitting element, an outer frame body provided with a through-hole in a bottom surface, provided on the substrate to locate the light-emitting section in the through-hole, and made of an insulator, and a cylindrical reflector in the outer frame body, including a first opening end and a second opening end having an area larger than the first opening end, and provided on the bottom surface with the first opening end. A step is absent in at least one part of the part between an inner wall surface of the through-hole and an inner wall surface of the reflector. An area of a third opening end on the substrate side of the through-hole is smaller than an area of a fourth opening end on the reflector side of the through-hole.Type: ApplicationFiled: March 15, 2013Publication date: November 21, 2013Applicants: Kabushiki Kaisha Toshiba, Toshiba Lighting & Technology CorporationInventors: Kenji Nezu, Hiroshi Matsushita, Yuichiro Takahara, Makoto Otsuka, Yasuhide Okada, Hiromi Nara, Erika Takenaka
-
Publication number: 20060173009Abstract: Osteoporosis and the like metabolic bone diseases have a high frequency of causing lumbago and the like pains and bone fracture, due to lowering of the bone strength caused by the reduction of bone mass. Accordingly, great concern has been directed toward the creation of a drug which can increase the bone mass and bone strength by controlling the whole bone metabolism. The pharmaceutical composition or combination product of the invention comprising a non-living body-derived non-peptide osteoblast differentiation promoting compound and a bisphosphonate having a bone resorption inhibitory action is useful as a bone mass increasing inducer which can increase the bone mass and/or bone strength by controlling the bone metabolism.Type: ApplicationFiled: June 30, 2004Publication date: August 3, 2006Inventors: Hiroyuki Kanoh, Koichiro Takahashi, Hiromi Nara, Tatsuhiko Yamanoi, Shinji Fukushima, Ryo Naito, Susumu Igarashi